Insights & news

Finland Will Increase Executive Powers in Relation to Medicines and Medical Devices to Tackle Medicine Shortages in Health Crises

  • 15/05/2020
  • Articles

In early May 2020, Finland notified to the European Commission (the “Commission”) a series of proposed measures to tackle medicine shortages (see, attached notification). The notification, based on Directive (EU) 2015/1535 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services, should allow the Commission and other Member States to offer their view on the compatibility of the proposed measures with EU pharmaceutical law and with the free movement of goods principle.
The Finnish government submitted to Parliament a draft Law which, if adopted, will amend a series of existing laws as follows:

  • The Ministry of Social Affairs and Health will have the power to restrict the distribution, sale and release for consumption of medicines. It will also be able to prioritise the distribution of specific medicines or impose a range of usage conditions. Additionally, flanking measures will make it easier for the Ministry to enforce these new powers.
  • The Finnish Medicines Agency and the Ministry of Social Affairs and Health will be given broader powers to run mandatory reserve supplies of medicines by, for example, requiring these supplies to be located in Finland.
  • The Ministry of Social Affairs and Health will have more powers to tackle communicable diseases, both with regard to medicines preventing such diseases or treating related conditions and with regard to medical devices for which no conformity assessment has yet been issued.

While the outbreak of Covid-19 has prompted this initiative, the Finnish government expressly seeks to bolster executive powers to tackle other health crises as well. It points out that Finland is particularly vulnerable given its dependency on imported medicines.


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 29/05/2020
    • Articles

    European Commission Presents EU4Health Programme

    On 28 May 2020 the European Commission (the Commission) presented details of its new, stand-alone EU4Health Programme, a proposal to commit considerable EU resources to health during the 2021-2027 period (EU4Health). The budget which the Commission proposes to earmark for EU4Health, EUR 9.4 billion, reflects a more than 20-fold increase over the funds previously dedicated to this policy area (EUR 413 million). The Commission first made its plan public as part of the presentation of ‘Next Generation EU’, a EURO 750 billion recovery plan to be embedded in and added to the long term overall EU budget for the 2021-2027 period (see, Van Bael & Bellis Life Sciences News Alert, 28 May 2020).

    Read more
    • 28/05/2020
    • Articles

    Next Generation EU - European Commission Proposes Significant Funding and Expanded EU Health Programme

    The European Commission (the Commission) published on 27 May 2020 its proposal for a major recovery plan and put forward a new EUR 750 billion recovery instrument called ‘Next Generation EU’ that would be embedded in and added to the long term EU budget (itself worth some EUR 1,100 billion between 2021 and 2027). The money from Next Generation EU would be available to the Member States in the form of both grants (EUR 500 billion) and loans (EUR 250 billion). The focus of the recovery plan is the green and digital transition but the plan also has a substantial health component, at times intertwined with green and digital aspects.

    Read more
    • 26/05/2020
    • Articles

    Dutch Competition Authority Supports Cooperation in Distributing Essential Medicines

    The Dutch competition authority, Autoriteit Consument en Markt (ACM), published a statement indicating that it supports the cooperation between hospitals, hospital pharmacies and pharmaceutical wholesalers to reduce or avert shortages of 14 essential medicines for which demand during the Covid-19 crisis has soared (see, attachment). ACM took the position in response to a request made by Landelijk Coördinatiecentrum Geneesmiddelen (LCG), an organisation established in April 2020 to secure supplies of medicines for intensive care treatment and surgery in hospitals. LCG organises the procurement and distribution of these medicines. ACM said that it did not expect any competition problems to arise. It explained that this form of cooperation was transparent, temporary and necessary to prevent both national and local medicine shortages. It added that the measures adopted by LCG did not extend beyond what is necessary to achieve this goal. ACM also pointed out that safeguards had been put in place to avoid the exchange of information among wholesalers regarding prices or stocks. The ACM’s position is in line with that taken by other competition authorities around Europe to make sure that supplies of essential goods such as medicines and foodstuffs would not be curtailed (see e.g., Van Bael & Bellis Life Sciences News Alerts of 9 April 2020 and 29 April 2020).

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *